Skip to content

CorMedix CRMD Contract revenue — Total Revenue

Other product segments

DefenCath
$97.51M+150%
Melinta Portfolio
$24.41M

Similar metrics at other companies

Ligand Pharmaceuticals logo
LGNDContract revenue — Total revenues and income
$110K-97.5%
Ligand Pharmaceuticals logo
LGNDContract revenue and income — Total revenues and income
$110K-97.5%
Ligand Pharmaceuticals logo
LGNDContract revenue and other income — Total revenues and other income
$110K-97.5%
Rigel Pharmaceuticals logo
RIGLContract revenues from collaborations — Revenue recognized
$3.9M-60.2%
Washington Trust Bancorp logo
WASHTotal Revenues — Revenue from contracts with customers
$13.08M-32.6%
Kodiak Gas Services logo
KGSContract Services — Revenue
$306.99M+6.2%

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's contract revenue — total revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's contract revenue — total revenue?
CorMedix (CRMD) reported contract revenue — total revenue of $5.51M in Q1 2026.
What does contract revenue — total revenue mean?
This metric represents the total revenue generated specifically from contractual arrangements, such as licensing agreements, research collaborations, or service-based partnerships. It reflects the company's ability to monetize its intellectual property or specialized capabilities through external business relationships rather than direct product sales. Monitoring this stream helps investors assess the diversification of income sources and the strategic value of the company's partnership ecosystem.